Results 141 to 150 of about 5,892 (166)

Correction to "Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?" [PDF]

Child Kidney Dis
Baek HS, Cho MH.
europepmc   +1 more source

Clinical trial on the pharmacokinetics, pharmacodynamics and safety of tolvaptan in healthy Chinese males: an open-label, single and multiple dosage, parallel group study. [PDF]

Front Pharmacol
Liu H, Liu T, Liu M, Zheng X, Zhong W, Zhao Q, Jiang J, Hu P, Li Y.   +8 more
europepmc   +1 more source

SAR-Guided Scaffold Innovation of Selective V₂R Antagonists: Therapeutic Frontiers in ADPKD. [PDF]

ACS Med Chem Lett
Shi H, Li Y, Liang SH.
europepmc   +1 more source

Sodium-Glucose Cotransporter-2 Inhibitors in ADPKD: Time to Integrate Cardiovascular Outcomes. [PDF]

Kidney Int Rep
Catania M, Rivera RF, Kola K, De Rosa LI, Paolisi M, Bianca P, Vezzoli G, Sciarrone Alibrandi MT.   +7 more
europepmc   +1 more source

Diuretic strategies in acute heart failure: a systematic review and network meta-analysis of randomized clinical trials. [PDF]

Eur Heart J Cardiovasc Pharmacother
Cannatà A, Anastasia G, De Marzo V, Caspi O, Bromage D, Porto I, Savarese G, McDonagh T, Cox ZL, Ameri P.   +9 more
europepmc   +1 more source

Tolvaptan vs Fluid Restriction in Moderate-Profound Hyponatremia: An Open-Label Randomized Clinical Trial.

J Clin Endocrinol Metab
Warren AM, Grossmann M, Hoermann R, Lin R, Zajac JD, Russell N.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

In Vitro P-Glycoprotein Interactions and Steady-State Pharmacokinetic Interactions Between Tolvaptan and Digoxin in Healthy Subjects

Journal of Clinical Pharmacology, 2011
Suresh Mallikaarjun, Patricia Bricmont, Shin-Ichi Ninomiya   +2 more
exaly  

Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database

Drug Safety, 2015
Paul B Watkins, James H Lewis
exaly  

Mechanisms of tolvaptan-induced toxicity in HepG2 cells

Biochemical Pharmacology, 2015
Yuanfeng Wu, Frederick A. Beland, Jia-Long Fang   +2 more
exaly